Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors
- 31 March 2004
- journal article
- review article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 58 (3), 941-949
- https://doi.org/10.1016/j.ijrobp.2003.09.094
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancerBritish Journal of Cancer, 2006
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2003
- ZD1839 (‘Iressa’) an EGFR tyrosine kinase inhibitor radiosensitizes glioblastoma multiforme by inhibition of a cell survival pathwayInternational Journal of Radiation Oncology*Biology*Physics, 2002
- IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancerSeminars in Oncology, 2002
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor InhibitionJournal of Clinical Oncology, 2002
- EGFR and its mutant EGFRvIII as modulators of tumor cell radiosensitivityInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Radiation-induced Release of Transforming Growth Factor α Activates the Epidermal Growth Factor Receptor and Mitogen-activated Protein Kinase Pathway in Carcinoma Cells, Leading to Increased Proliferation and Protection from Radiation-induced Cell DeathMolecular Biology of the Cell, 1999
- Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cellsOncogene, 1998
- Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylationOncogene, 1997